A5040926660- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Sarcoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- CAR-T cell therapy research
- Cancer therapeutics and mechanisms
- Global Public Health Policies and Epidemiology
- Healthcare cost, quality, practices
- PI3K/AKT/mTOR signaling in cancer
- Insurance and Financial Risk Management
- Ubiquitin and proteasome pathways
- Cancer-related cognitive impairment studies
- Advanced Breast Cancer Therapies
- Alkaline Phosphatase Research Studies
- Pancreatitis Pathology and Treatment
- Healthcare Systems and Public Health
- Viral Infectious Diseases and Gene Expression in Insects
- Gastrointestinal Tumor Research and Treatment
- Cancer Mechanisms and Therapy
- Neurofibromatosis and Schwannoma Cases
Cleveland Clinic
2024-2025
WinnMed
2022-2024
Mayo Clinic
2022-2024
Mayo Clinic in Arizona
2022-2024
Heidelberg University
2023
University Hospital Heidelberg
2023
Memorial Sloan Kettering Cancer Center
2023
Johns Hopkins Medicine
2018-2019
Johns Hopkins University
2018-2019
Indian Institute of Information Technology Allahabad
2017
Background/Objectives: Chimeric antigen receptor T-cell therapy (CAR-T) has become a key treatment option for relapsed/refractory multiple myeloma (RRMM), but factors impairing fitness may diminish efficacy. Our exploratory analysis aimed to evaluate the impact of prior with selinexor-containing regimen on CAR-T outcomes RRMM patients. Methods: Data this retrospective cohort study were sourced from electronic medical records at two US academic centers. Kaplan-Meier estimates assessed...
Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well-characterized given the exclusion these from clinical trials. Herein, we evaluated relapsed/refractory multiple myeloma and RI treated standard-of-care teclistamab. was defined as creatinine clearance (CrCl) <40mL/min. CrCl <30mL/min or dialysis dependence were severe RI. Of 384 included patients, 81 (21%) had RI, including 45 (18%) 18 (5%) on dialysis. Patients more likely to be older (median...
Multiple myeloma (MM) is a plasma cell malignancy that characterized by diverse clinical presentations. Although biochemical assessment of disease activity commonly used to monitor treatment response, findings on magnetic resonance imaging and positron emission tomography (PET)/computed (CT), among other modalities, have proven harbor prognostic value. We sought corroborate these examining the significance fluorodeoxyglucose PET/CT scanning in setting newly diagnosed MM. retrospectively...
Abstract Lenalidomide‐containing (R) triplet and quadruplet regimens are the standard of care for multiple myeloma (MM) have been shown to increase risk thrombosis. The association between thromboembolism (TE) survival in novel multidrug era is not yet delineated. In this study, we evaluated incidence TE during first year MM diagnosis, its with type induction regimen, impact on overall survival. We studied 672 newly diagnosed (NDMM) patients who received a or lenalidomide‐based at Mayo...
Abstract Clinical trials evaluating chimeric antigen receptor (CAR) T‐cell therapy in relapsed/refractory multiple myeloma (RRMM) have typically excluded patients with AL amyloidosis. As a result, there are limited data on the safety and efficacy of CAR this patient population. We retrospectively reviewed eight consecutive RRMM amyloidosis who were treated standard care therapy. Cytokine release syndrome was seen 75% (grade ≥3: 0%) immune effector cell‐associated neurotoxicity 1) only one...
Patients with multiple myeloma (MM) who do not respond to initial therapy have worse outcomes than primary responders, and effective treatments are lacking in this population. However, the of refractory disease modern treatment era yet been studied. We reviewed patients MM treated triplet/quadruplet at our institution assess incidence impact salvage therapies identified 1127 patients, whom 1086 were evaluated for hematologic responses after 4 6 cycles. Of these, 93.3% (1013) had evidence...
Abstract Background Because of the rarity desmoplastic small round cell tumors (DSRCT), there is a lack data describing patterns care and survival for these patients. Using national tumor registry, current study sought to describe clinical outcomes patients with DSCRT. Methods Data from National Cancer Database were used identify 491 aged 18 years or older diagnosed DSRCT between 2004 2014. Multivariable Cox proportional hazards regression analysis was factors associated overall (OS)....
Abstract Objectives and Methods We conducted a multicenter retrospective study to analyze the safety efficacy of DPd versus DKd in daratumumab naïve RRMM patients treated real‐world practice. Results A total 187 with were included analysis; 128 received DPd, 59 DKd. vast majority (80%) had lenalidomide refractory disease nearly 50% bortezomib disease. The overall response complete rates 76% 34% group 80% 51% group, respectively. With median follow up 36 months for entire patient population,...
Abstract Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myeloma (MM). It remains debatable if resistance varies among MM refractory standard doses vs low dose maintenance doses. In this study, we assessed outcomes with subsequent therapies patients lenalidomide. We retrospectively reviewed all our institution who received line containing regimens, and progression free survival (PFS) overall for these second therapy,...
Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution plasma cell-directed therapy and consideration therapeutic exchange (TPE), with goal rapid reduction serum free light chain (sFLC). However, role TPE continues to remain a subject debate. The this retrospective bi-institutional study was evaluate clinical outcomes in combination systemic therapy. Eighty patients were included analysis, whom 72.5% had ≥50% drop their initial involved sFLC. At 3 months...
Multiple Myeloma patients eligible for autologous hematopoietic transplantation (AHT) typically receive 3-6 cycles of induction therapy before transplant. The last cycle is completed 2-4 weeks prior to mobilization. We evaluated the impact time interval between end and AHT on progression-free survival (PFS) overall (OS). A total 1055 who underwent were identified. median transplant (TTT) was 33 days (27-42 quartile range). Patients with less than TTT had significantly prolonged PFS (35.6 vs....
As patients with relapsed/refractory multiple myeloma (RRMM) continue to live longer, they might get exposed most available drugs and drug classes during the disease course. For such late line RRMM or among without access novel therapies, retreatment a that had previously been refractory be one option. In this retrospective study, we describe 315 at our institution were retreated to. We found an overall response rate of 56.2%, median progression free survival (PFS) 11 months retreatment....
e20011 Background: Drug refractoriness is an important factor determining choice of next therapy and prognosis in multiple myeloma (MM). It debatable whether to a drug varies among patients (pts) with MM progressing on different administration schedules the drug. Outcomes pts refractory doses lenalidomide have been previously described, but similar data about proteasome inhibitors (PIs) are limited. In this study, we assessed impact bortezomib (V) outcomes subsequent therapies pts. Methods:...
e20032 Background: The introduction of anti-CD38 antibodies (daratumumab) in the treatment landscape multiple myeloma (MM) has increased progression-free survival (PFS) recent years. Still, ideal combination (Dara-IMiD vs. Dara-PI) these drugs patients with relapsed MM is unclear. Methods: We reviewed treated daratumumab as second-line therapy at our institution from 2016 to 2022 assess outcomes different therapies. used Kaplan-Meier method estimate PFS first relapse. Results: identified 329...
8051 Background: Patients with multiple myeloma (MM) that do not respond to initial therapy have worse outcomes compared primary responders, and effective treatments are lacking in this population. However, the of refractory disease modern treatment era been studied. Methods: From 2007-2019, we reviewed MM patients treated triplet/quadruplet our institution assess incidence impact salvage therapies Primary was defined as either progressive or stable at 4-6 cycles. The Kaplan-Meier estimates...